

TABLE OF CONTENTS

EXECUTIVE SUMMARY.....	6	4.5 Groups of manufacturing companies financial indicators (2016)	107
INTRODUCTION.....	8		
1. GENERAL INFORMATION.....	9	4.6 Groups of importing companies financial indicators (2016).....	108
1.1 Industry definition.....	10		
1.2 Industry general facts & figures.....	11	4.7 Consolidated balance sheet Assets-Liabilities structure of the manufacturing pharmaceutical companies.....	109
1.3 Drug distribution channel.....	12		
1.4 Industry characteristics.....	13	4.8 Consolidated balance sheet Assets-Liabilities structure of the importing pharmaceutical companies.....	110
1.5 Expenditure on research and development (R&D).....	14		
2. INSTITUTIONAL FRAMEWORK.....	15	4.9 Manufacturing companies financial results growth.....	111
2.1 Institutional framework.....	16		
2.2 Pricing.....	31	4.10 Importing companies financial results growth.....	115
2.3 Prescription.....	48		
3. DEMAND.....	51	4.11 Comparative assessment of leading manufacturing companies' financial indicators (2016).....	119
3.1 Determinants of demand for pharmaceutical companies products	52		
3.2 Analysis of selected determinants of demand	55	4.12 Comparative assessment of leading importing companies' financial indicators (2016).....	122
4. SUPPLY.....	87		
4.1 Turnover index for basic pharmaceutical products.....	89	5. VALUATION OF COMPANIES OF THE INDUSTRY	125
4.2 Leading manufacturing companies.....	90	5.1 Valuation methodology.....	126
4.3 Leading importing companies.....	93	5.2 Valuation of the manufacturing companies of the industry (2012-2016).....	127
4.4 Financial analysis of the industry (2010-2016)	98		

TABLE OF CONTENTS

5.3 Valuation of the importing companies of the industry (2012-2016).....		6.14 Porter's five forces.....	145
6.MARKET.....	128	7. INTERNATIONAL MARKET.....	149
6.1 Domestic market size of pharmaceutical companies (2009-2016)	129	7.1 Structure of the International market (2015-2016).....	150
6.2 Domestic market size of manufacturing pharmaceutical companies (2009-2016)	130	7.2 Geographical breakdown of drug costs.....	
6.3 Domestic market size of importing pharmaceutical companies (2009-2016)	131	7.3 Pharmaceutical costs for research development.....	152
6.4 Drug sales.....	132	7.4 Ten largest global pharmaceutical companies International.....	153
6.5 Pharmaceuticals domestic production	133	7.5 Acquisitions and mergers in global pharmaceutical market.....	154
6.6 Gross added value of basic pharmaceutical products and formulations.....	135	7.6 Evolution of the pharmaceutical industry in Europe.....	155
6.7 External trade of pharmaceutical products.....	136	7.7 European market-Production of pharmaceuticals products.....	156
6.8 Structure of external trade of pharmaceutical products (2016).....	137	7.8 European market-Employed.....	157
6.9 Comparative advantage of industry exports.....	138	7.9 European market-Imports of pharmaceutical products.....	159
6.10 External trade of drugs.....	139	7.10 European market-Exports of pharmaceutical products.....	160
6.11 Generic medicines domestic market size in pharmacies-hospitals(2011-2016)	140	7.11 European market-Trade balance of pharmaceutical products.....	161
6.12 Number of clinic and clinical beds.....	141	7.12 The biggest trading partners in the EU pharmaceutical.....	
6.13 Number and geographical allocation of pharmacies.....	142		162

TABLE OF CONTENTS

7.13 European market-pharmaceutical expense....	163	A. Capital structure and financial leverage indicators.....	236
7.14 European market-Distribution of the retail price of drugs.....	164	B. Liquidity indicators.....	260
7.15 European market-VAT rates.....	165	C. Activity indicators.....	272
7.16 European market-Generics.....	166	D. Performance indicators.....	296
7.17 Research and development in the European pharmaceutical market.....	168	Financial formulas.....	316
7.18 Innovation performance in EU-28.....	169	SOURCES & BIBLIOGRAPHY	317
8. CONCLUSIONS-PROSPECTS	170		
8.1 SWOT analysis.....	171		
8.2 Main findings- Prospects.....	172		
APPENDIX I			
Financial indicators of major manufacturing pharmaceutical companies (2010-2016).....	174		
A. Capital structure and financial leverage indicators.....	175		
B. Liquidity indicators.....	193		
C. Activity indicators.....	202		
D. Performance.....	220		
APPENDIX II			
Financial indicators of major importing pharmaceutical companies (2010-2016).....	235		